Grapiprant - AskAt

Drug Profile

Grapiprant - AskAt

Alternative Names: 423; AAT-007; ARY 007; CJ-023; CJ-023,423; CJ-23423; MR-10A7; RQ-00000007; RQ-7

Latest Information Update: 10 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer AskAt; Kyn Therapeutics; Maruishi Pharmaceutical
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Benzene derivatives; Imidazoles; Pyridines; Small molecules; Sulfonamides; Sulfonylureas
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Colorectal cancer
  • No development reported Acute pain; Autoimmune disorders; Cancer; Cancer pain; Hypersensitivity; Inflammation; Postoperative pain

Most Recent Events

  • 04 Oct 2018 Arrys Therapeutics in collaboration with Merck Sharp & Dohme plans a phase I/II trial for Non-small Cell Lung Cancer (Combination therapy, Late-stage disease) in USA , (NCT03696212)
  • 21 Sep 2018 Arrys Therapeutics and Merck plans a phase I trial for Colorectal Cancer (Late stage disease, Metastatic disease, Second line therapy or greater) in USA, in September 2018 (NCT03658772)
  • 20 Sep 2018 Phase-I clinical trials in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT03658772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top